BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34144374)

  • 21. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).
    Efebera YA; Geyer S; Andritsos L; Vasu S; Jaglowski S; Bingman A; Blum W; Klisovic R; Hofmeister CC; Benson DM; Penza S; Elder P; Cortright K; Kitzler R; Coombes K; O'Donnell L; Daneault B; Bradbury H; Zhang J; Chen X; Garman S; Ranganathan P; Yu X; Hofstetter J; Yu J; Garzon R; Scrape SR; Lozanski G; Devine SM
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):71-9. PubMed ID: 26256940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
    Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
    Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review.
    Ito A; Kim SW; Fukuda T
    Int J Hematol; 2022 Sep; 116(3):309-314. PubMed ID: 35653054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
    Kanate AS; Hari PN; Pasquini MC; Visotcky A; Ahn KW; Boyd J; Guru Murthy GS; Rizzo JD; Saber W; Drobyski W; Michaelis L; Atallah E; Carlson KS; D'Souza A; Fenske TS; Cumpston A; Bunner P; Craig M; Horowitz MM; Hamadani M
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1295-1302. PubMed ID: 28412518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of Gut Colonization by Antibiotic-Resistant Bacteria on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Single-Center Study.
    Bilinski J; Robak K; Peric Z; Marchel H; Karakulska-Prystupiuk E; Halaburda K; Rusicka P; Swoboda-Kopec E; Wroblewska M; Wiktor-Jedrzejczak W; Basak GW
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1087-1093. PubMed ID: 26900084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States.
    Ison MG; Marty FM; Chao N; Moon SH; Zhang Z; Chandak A
    Transpl Infect Dis; 2022 Aug; 24(4):e13866. PubMed ID: 35598293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
    Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
    Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the Polish Pediatric Group for Hematopoietic Stem Cell Transplantation.
    Zając-Spychała O; Wachowiak J; Pieczonka A; Siewiera K; Frączkiewicz J; Kałwak K; Gorczyńska E; Chybicka A; Czyżewski K; Jachna-Sawicka K; Wysocki M; Klepacka J; Goździk J; Zaucha-Prażmo A; Kowalczyk JR; Styczyński J
    Transpl Infect Dis; 2016 Oct; 18(5):690-698. PubMed ID: 27479544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.
    Epperla N; Ahn KW; Litovich C; Ahmed S; Battiwalla M; Cohen JB; Dahi P; Farhadfar N; Farooq U; Freytes CO; Ghosh N; Haverkos B; Herrera A; Hertzberg M; Hildebrandt G; Inwards D; Kharfan-Dabaja MA; Khimani F; Lazarus H; Lazaryan A; Lekakis L; Murthy H; Nathan S; Nishihori T; Pawarode A; Prestidge T; Ramakrishnan P; Rezvani AR; Romee R; Shah NN; Sureda A; Fenske TS; Hamadani M
    J Hematol Oncol; 2019 Jan; 12(1):6. PubMed ID: 30630534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nutritional interventions in patients with graft-versus-host disease.
    Seguy D; Hueso T
    Curr Opin Clin Nutr Metab Care; 2023 Sep; 26(5):455-462. PubMed ID: 37389472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation.
    Ito A; Kitano S; Tajima K; Kim Y; Tanaka T; Inamoto Y; Kim SW; Yamamoto N; Fukuda T; Okamoto S
    Int J Hematol; 2020 Jan; 111(1):120-130. PubMed ID: 31641956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis.
    Johnson BH; Taylor A; Kim G; Drahos J; Yang J; Akbari M; Shah NN
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):834-841. PubMed ID: 30625389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of broad-spectrum antibiotic exposures and multidrug-resistant gram-negative bacteremia on hematopoietic cell transplantation outcomes.
    Kaundal S; Jandial A; Singh H; Chopra M; Kasudhan KS; Khaire N; Khadwal A; Prakash G; Jain A; Suri V; Patil A; Arora A; Sharma V; Ray P; Malhotra P; Lad DP
    Transpl Infect Dis; 2021 Oct; 23(5):e13717. PubMed ID: 34431187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting.
    Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M
    Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease.
    Burgos da Silva M; Ponce DM; Dai A; M Devlin S; Gomes ALC; Moore G; Slingerland J; Shouval R; Armijo GK; DeWolf S; Fei T; Clurman A; Fontana E; Amoretti LA; Wright RJ; Andrlova H; Miltiadous O; Perales MA; Taur Y; Peled JU; van den Brink MRM
    Blood; 2022 Dec; 140(22):2385-2397. PubMed ID: 35969834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TNFAIP8 Deficiency Exacerbates Acute Graft Versus Host Disease in a Murine Model of Allogeneic Hematopoietic Cell Transplantation.
    Kumari R; Palaniyandi S; Strattan E; Huang T; Kohler K; Jabbour N; Dalland J; Du J; Kesler MV; Chen YH; Hildebrandt GC
    Transplantation; 2020 Mar; 104(3):500-510. PubMed ID: 31634333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
    Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.
    Nikolaenko L; Chhabra S; Biran N; Chowdhury A; Hari PN; Krishnan A; Richter J
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):407-414. PubMed ID: 32249196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation.
    Severyn CJ; Siranosian BA; Kong ST; Moreno A; Li MM; Chen N; Duncan CN; Margossian SP; Lehmann LE; Sun S; Andermann TM; Birbrayer O; Silverstein S; Reynolds CG; Kim S; Banaei N; Ritz J; Fodor AA; London WB; Bhatt AS; Whangbo JS
    JCI Insight; 2022 Apr; 7(7):. PubMed ID: 35239511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.